Biopharmaceutical
Japan
Sweden
Treatments
Rare
Kidney
M&A Advisory
Lazard
Full Credential Description
Calliditas Therapeutics. Japan, Sweden. Announced Date 28/05/2024. Closed Date 30/07/2024. Deal value: $1049m. Asahi Kasei announces a public cash offer to acquire all shares in Calliditas. Industry: Calliditas Therapeutics is a biopharmaceutical company focused on developing treatments for rare kidney diseases.